PRURITUS IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) TREATED WITH OBETICHOLIC ACID (OCA)

被引：0

作者：

Younossi, Zobair M. ^{[1
,2
,3
]}

Stepanova, Maria ^{[4
]}

Nader, Fatema ^{[4
]}

Bonacci, Martin ^{[5
]}

Wong, Bruce ^{[5
]}

Loomba, Rohit ^{[6
]}

Rinella, Mary E. ^{[7
]}

Noureddin, Mazen ^{[8
]}

Harrison, Stephen A. ^{[9
]}

机构：

[1] Inova Hlth Syst, Inova Med, Falls Church, VA USA

[2] Inova Hlth Syst, Betty & Guy Beatty Ctr Integrated Res, Falls Church, VA USA

[3] Inova Fairfax Med Campus, Dept Med, Ctr Liver Dis, Falls Church, VA USA

[4] Ctr Outcomes Res Liver Dis, Washington, DC USA

[5] Intercept Pharmaceut Inc, New York, NY USA

[6] Univ Calif San Diego, NAFLD Res Ctr, Div Gastroenterol, Dept Med, La Jolla, CA 92093 USA

[7] Northwestern Univ, Feinberg Sch Med, Evanston, IL 60208 USA

[8] Cedars Sinai Med Ctr, Fatty Liver Program, Los Angeles, CA 90048 USA

[9] Pinnacle Clin Res, San Antonio, TX USA

来源：

HEPATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

1690

引用

页码：1029 / 1030

页数：2

共 50 条

[41] Erratum: miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
Pedro M Rodrigues
Marta B Afonso
André L Simão
Catarina C Carvalho
Alexandre Trindade
António Duarte
Pedro M Borralho
Mariana V Machado
Helena Cortez-Pinto
Cecília MP Rodrigues
Rui E Castro
Cell Death & Disease, 2017, 8 : e2825 - e2825
[42] Obeticholic Acid Impact on Quality of Life in Patients With Nonalcoholic Steatohepatitis: REGENERATE 18-Month Interim Analysis
Younossi, Zobair M.
Stepanova, Maria
Nader, Fatema
Loomba, Rohit
Anstee, Quentin M.
Ratziu, Vlad
Harrison, Stephen
Sanyal, Arun J.
Schattenberg, Jorn M.
Barritt, A. Sidney
Noureddin, Mazen
Bonacci, Martin
Cawkwell, Gail
Wong, Bruce
Rinella, Mary
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2022, 20 (09) : 2050 - +
[43] Nonalcoholic steatohepatitis (NASH) drugs market
Sorcha Cassidy
Basharut A. Syed
Nature Reviews Drug Discovery, 2016, 15 : 745 - 746
[44] Safety, Pharmacokinetics and Pharmacodynamics of Obeticholic Acid in Subjects with Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Alkhouri, Naim
Edwards, Jeffrey
Poordad, Fred
Lawitz, Eric J.
Lee, Lois
Karan, Sharon B.
Campagna, Jason
MacConell, Leigh
HEPATOLOGY, 2018, 68 : 974A - 974A
[45] Fatty acid levels in nonalcoholic steatohepatitis (NASH) and fatty liver.
Lau, Y
Hatch, G
Minuk, GY
HEPATOLOGY, 1999, 30 (04) : 546A - 546A
[46] Changes in insulin sensitivity and improvements in liver histology in patients with nonalcoholic steatohepatitis (NASH) treated with pioglitazone (PIO)
Freedman, R
Uwaifo, G
Lutchman, G
Promrat, K
Park, Y
Kleiner, D
Yanovski, J
Hoofnagle, J
DIABETES, 2003, 52 : A76 - A76
[47] Predictive Factors for Nonalcoholic Steatohepatitis (NASH) in Patients with Nonalcoholic Fatty Liver Disease (NAFLD)
Fierbinteanu-Braticevici, Carmen
Baicus, Cristian
Tribus, Laura
Papacocea, Raluca
JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2011, 20 (02) : 153 - 159
[48] Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) in Patients with Morbid Obesity
Manno, Emilio
OBESITY SURGERY, 2010, 20 (06) : 811 - 811
[49] Biopsy rate and nonalcoholic steatohepatitis (NASH) in patients with nonalcoholic fatty liver disease (NAFLD)
Gerhardt, Florian
Petroff, David
Blank, Valentin
Boehlig, Albrecht
van Boemmel, Florian
Wittekind, Christian
Berg, Thomas
Karlas, Thomas
Wiegand, Johannes
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (06) : 706 - 711
[50] Combined Administration of a Long-Acting Glucagon-like Peptide-1 (GLP-1) Receptor Agonist with FXR Agonist Obeticholic Acid (OCA) Exerts Benefits on Aspects of Nonalcoholic Steatohepatitis (NASH) in Mice
Jouihan, Hani
Will, Sarah
Guionaud, Silvia
Ravn, Peter
Trevaskis, James L.
DIABETES, 2016, 65 : A316 - A316

← 1 2 3 4 5 →